Expression of co-stimulatory molecules B7-2 and PD-L1 on peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection

作     者：Lingxia Fei Shipin Wu Hongtao Chen 

作者机构：Department of Infectious Disease Shenzhen People's Hospitalthe Second Clinical Medical College of Jinan University Shenzhen 518020 China 

出 版 物：《Journal of Nanjing Medical University》 (南京医科大学学报（英文版）)

年 卷 期：2009年第23卷第5期

页      面：347-351页

学科分类：090603[农学-临床兽医学] 083002[工学-环境工程] 0830[工学-环境科学与工程（可授工学、理学、农学学位）] 07[理学] 08[工学] 09[农学] 0906[农学-兽医学] 0903[农学-农业资源与环境] 0713[理学-生态学] 

主　　题：Co-stimulatory molecule B7-2 PD-L1 Hepatitis B virus 

摘      要：Objective： To explore the roles of the expression of the co-stimulatory molecule, B7-2, and the co-inhibitory molecule, PD-L1, on peripheral blood mononuclear cells in the mechanism of immunotolerance in chronic hepatitis B virus infection. Methods： Thirty HBV infected patients in the immunoreactive phase and 20 patients in the immunotolerant phase were enrolled in the study, while 20 healthy volunteers were used as controls. RT- PCR and real-time PCR methods were used to detect the expression levels of B7-2 and PD-L1 mRNA in peripheral blood mononuclear cells in chronic HBV infected patients. Results： The B7-2 expression in irnrnunoreactive and immunotolerant patients was significantly lower than that in the controls （P all 〈 0.01 ）; B7-2 expression in immunoreactive patients was significantly lower than in immunotolerant patients （P 〈 0.01）. PD-L1 expression in irnmunoreactive patients and immunotolerant patients was significantly higher than that in normal controls （P all 〈 0.01）. The PD-L1/BT-2 ratios in immunoreactive and immunotolerant patients were significantly higher than that of the healthy controls （P all 〈 0.01）; the PD-L1/ B7-2 ratio was significantly higher in the immunoreactive patients than in the immunotolerant patients （P 〈 0.01）. Conclusion： In chronic HBV infection, changes in the expression of co-stimulatory and co-inhibitory molecules imply a protective adjustment against the patient＇ s immune response that may result in increased immunotolerance and persistent HBV infection.